Publications

In Vitro Activity of WCK 5999, a Carbapenem/β-lactamase Inhibitor Combination Tested against Contemporary KPC-producing Enterobacteriaceae, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-421

In Vitro Activity of WCK 5999 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a Worldwide Surveillance Program (2015), Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-476

WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Gram-negative Organisms Producing Clinically Relevant β-Lactamases, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-447

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Antimicrobial Resistant Gram-negative Bacilli, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-446

WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Enterobacteriaceae Clinical Isolates Collected Worldwide (2015), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-445

Antimicrobial Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter spp. Collected Worldwide (2015), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-478

WCK 5222 (Cefepime-Zidebactam) In Vitro Time-kill Studies against Pseudomonas aeruginosa and Acinetobacter baumannii Isolates with Characterized β-lactamases, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-477

In Vitro Activity of Lactone Ketolide WCK 4873 When Tested Against Contemporary Community-Acquired Bacterial Pneumonia Pathogens from a Global Surveillance Program, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-476

In Vitro Activity of WCK 4873 (Nafithromycin) against Resistant Subsets of Streptococcus pneumoniae From a Global Surveillance Program (2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-455

WCK 4282 (High-Dose Cefepime-Tazobactam) Disk Diffusion Quality Control Ranges Using a Multi-laboratory Study Design, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-018

Enhanced Activity of WCK 4282 (Cefepime-Tazobactam) Against KPC-Producing Enterobacteriaceae Collected Worldwide When Tested in Physiological Conditions, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-427

In Vitro Activity of WCK 771, a Benzoquinolizine Fluoroquinolone (Levonadifloxacin) when Tested Against Contemporary Gram-Positive and -Negative Bacteria from a Global Surveillance Program, Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-456

Activity of Telavancin Against a Global Collection of Staphylococcus aureus Causing Bacteremia (2011-2014), Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-335

Activity of TelavancinAgainst Gram-positive Pathogens Isolated from Bone and Joint Infections in North American, Latin American, European and Asia-Pacific Nations, Lead author: Jones RN, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-445

Synergistic Effect of Gram-positive Agents Tested in Combination with a New Polymyxin Derivative (SPR741) against Multidrug-resistant Gram-negative Pathogens, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-490

S-649266 MIC Quality Control Ranges in Iron-depleted cation-adjusted Mueller-Hinton Broth Using a Multi-laboratory Study Design, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-028

Oritavancin Longitudinal In Vitro Activity Against Gram-positive Organisms from USA Medical Centers: Results from the SENTRY Antimicrobial Surveillance Program for 2010-2014, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-345

Meropenem-vaborbactam (MER-VAB) Tested Against Contemporary Enterobacteriaceae Isolates from USA Hospitals, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-452

Evolving Linezolid Resistance Mechanisms in a Worldwide Collection of Enterococcal Clinical Isolates: Results from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-332

Gepotidacin (GSK2140944) In Vitro Activity Against Neisseria gonorrhoeae (MIC/MBC, Kill Kinetics, Checkerboard, PAE/SME Tests), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-461

Gepotidacin (GSK2140944) In Vitro Activity Against Gram-positive and Gram-negative Bacteria (MBC/MIC, Kill Kinetics, Checkerboard, PAE/SME Tests), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-460

In vitro Activity of Delafloxacin When Tested Against Contemporary Bacterial Pathogens
from the USA (2014), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-457

Activity of Ceftazidime-Avibactam Tested against Clinical Isolates of Antimicrobial Resistant Pseudomonas aeruginosa from United States Medical Centers (2012-2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-436

Ceftazidime-Avibactam Antimicrobial Activity When Tested against Gram-negative Bacteria Isolated from Intensive Care Unit (ICU) Patients with Pneumonia (2012-2014). Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-434

Ceftazidime-Avibactam Activity Tested against Eleven Enterobacteriaceae Species Producing KPC Enzymes, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-451

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents When Tested against Bacterial Isolates Causing Infection in Cancer Patients (2012-2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-435

Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure. by Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN and Bradley JS. published in Pediatr. Infect. Dis. J. 2016; 35 (7): 813-815

Antimicrobial Activity of Tigecycline and Cefoperazone/Sulbactam Tested against 14,850 Gram-negative Organisms from Europe and the Asia-Pacific Region (2013-2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Pseudomonas aeruginosa Isolated from Patients Hospitalised in Intensive Care Units in Europe, Turkey and Israel (2013-2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

In Vitro Activity of Plazomicin tested against Contemporary Clinical Isolates Collected in Asia-Pacific, Europe and Latin America, Lead author: Castanheira M, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Ceftolozane/Tazobactam Activity against Intra-Abdominal Pathogens Collected from 41 Medical Centres in Europe, Turkey and Israel (2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

ß-lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime-avibactam for the treatment of complicated urinary tract infections, Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Activity of Ceftolozane/Tazobactam tested against Organisms from Urinary Tract Pathogens Collected from 41 Medical Centres in Europe, Turkey and Israel (2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Enterobacteriaceae Isolated from Patients Hospitalised in Intensive Care Units from 19 European Countries, Turkey and Israel (2013-2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Antimicrobial Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Tested against Gram-negative Organisms from Medical Centers Located in Europe and the Asia-Pacific Region, Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Activity of Linezolid when Tested Against Contemporary European Bacterial Clinical Isolates (2015), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Analysis of the activity of telavancin tested against a global collection of Staphylococcus aureus clinical isolates responsible for documented hospital-acquired pneumonia (2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Oritavancin activity tested against European staphylococcal clinical isolates and resistant subsets inlcuding those with reduced susceptibility to daptomycin, teicoplanin or vancomycin (2010-2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

WCK 4282 (Cefepime-Tazobactam) MIC Quality Control Ranges Using a Multi-Laboratory Study Design, Lead author: Ross JE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Omadacycline Activity Tested Against European Bacterial Isolates from a Combined 2010-2011 Global Surveillance Program, Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

WCK4282 (High-Dose Cefepime-Tazobactam) Antimicrobial Activity against Gram-negative Organisms from United States and Latin America medical Centers (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

The Activity of Tedizolid against Gram-positive Pathogens Isolated from Patients in Medical Centres in Europe, Turkey and Israel: 2014 Surveillance, Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Delafloxacin activity tested against bacterial pathogens from 44 medical centres in Europe and Israel (2014), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN. published in J. Antimicrob. Chemother. 2016; 71 (1): 276-278

Nosocomial Candidiasis: Antifungal stewardship and the importance of rapid diagnosis. by Pfaller MA and Castanheira M published in Med. Mycol. 2016; 54 (1): 1-22

Klebsiella pneumoniae from a New York City hospital belonging to ST258 and carrying blaKPC-2- and blaVIM-4-encoding genes. by Castanheira M, Deshpande LM, Mills JC, Jones RN, Soave R, Jenkins SG and Schuetz AN published in Antimicrob. Agents. Chemother. 2016; 60 (3): 1924-1927

In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study. by Armstrong ES, Farrell DJ, Palchak M and Steenbergen JN published in Antimicrob. Agents. Chemother. 2016; 60 (1): 666-668

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. by Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M and Yamano Y published in J. Antimicrob. Chemother. 2016; 71 (3): 670-677

Beta-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: Clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN. published in Antimicrob. Agents. Chemother. 2015; 60 (3): 1328-1335